why choose us

First received: April 27, 2023

Clinical Trial: Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder

Study Status: Completed

Recruit Status: RECRUITING

Condition: Substance-Related Disorders

Study Type: INTERVENTIONAL


Official Title: Phase 2a Double-Blind Placebo-Controlled Trial of Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder

Brief Summary: This is a randomized, double-blind, placebo-controlled phase 2b pilot clinical trial to determine whether non-ergoline D3/D2/D1 dopamine (DA) receptor agonist rotigotine (RTG), in combination with treatment as usual, including individual or group behavioral therapy can a) reduce cocaine use and also b) increase brain activity in frontocortical areas of the brain, and, as a reflection of that - improve top-down cognitive control in persons with cocaine use disorder (CocUD).Rotigotine is a marketed…

Read more